Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of inhaled PC945 in lung transplant recipients with Aspergillus fumigatus colonisation
2018-000240-26Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of opelconazole in Aspergillus fumigatus colonization and pulmonary aspergillosis, sponsored by Pulmocide. Primary endpoint: Safety and tolerability of inhaled PC945. Started Oct 2018; status: terminated.
02
Drugs
opelconazole
03
Conditions
Aspergillus fumigatus colonizationpulmonary aspergillosis
Beyond the preview
Go deeper on 2018-000240-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000240-26.